Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.47 |
| ▸ | RELA | Q04206 | 1/20 | 0.47 |
| ▸ | BTK | Q06187 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9392474 | 1.00 | GAA (0.60) | GAANFKB1NFKB2RELABTK | |
| SCHEMBL555941 | 1.00 | GAA (0.60) | GAANFKB1NFKB2RELABTK | |
| SCHEMBL24111241 | 0.84 | GAA (0.44) | GAA | |
| SCHEMBL14159811 | 0.84 | GAA (0.51) | GAANFKB1NFKB2RELABTK | |
| SCHEMBL1271608 | 0.83 | GAA (0.54) | GAANFKB1NFKB2RELA | |
| SCHEMBL4915249 | 0.83 | GAA (0.54) | GAANFKB1NFKB2RELA | |
| SCHEMBL1036703 | 0.83 | GAA (0.54) | GAANFKB1NFKB2RELA | |
| SCHEMBL8357051 | 0.82 | GAA (0.50) | GAANFKB1NFKB2RELABTK | |
| SCHEMBL19824266 | 0.81 | GAA (0.51) | GAANFKB1NFKB2RELABTK | |
| SCHEMBL9846514 | 0.79 | GAA (0.49) | GAANFKB1NFKB2RELABTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 211 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12624053-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2026-05-12 | — | — | US | disclosed |
| US-20260070930-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT | 2026-03-12 | — | — | US | disclosed |
| US-20250388608-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2025-12-25 | — | — | US | disclosed |
| US-20250376464-A1 | Compounds for treatment a coronavirus infection | TRAWSFYNYDD THERAPEUTICS INC (US) | 2025-12-11 | — | — | US | disclosed |
| US-12465643-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2025-11-11 | — | — | US | disclosed |
| US-20250319187-A1 | RAS INHIBITORS | REVOLUTION MEDICINES INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-12409225-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2025-09-09 | — | — | US | disclosed |
| US-12403196-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2025-09-02 | — | — | US | disclosed |
| US-20250255964-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2025-08-14 | — | — | US | disclosed |
| US-20250242029-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT | 2025-07-31 | — | — | US | disclosed |
| US-5475136-A | Inhibitors of HIV protease useful for the treatment of AIDS | ELI LILLY AND COMPANY (US) | 1995-12-12 | — | — | US | disclosed |
| EP-0673388-A1 | DOUBLE CHAIN PEPTIDE COMPOUNDS HAVING HEMOREGULATORY ACTIVITY | NYCOMED IMAGING AS (NO) | 1995-09-27 | — | — | EP | disclosed |
| US-5434265-A | Inhibitors of HIV protease | ELI LILLY AND COMPANY (US) | 1995-07-18 | — | — | US | disclosed |
| WO-1995009843-A1 | HIV PROTEASE INHIBITORS | AGOURON PHARMACEUTICALS, INC. (US) | 1995-04-13 | — | — | WO | disclosed |
| WO-1994022841-A1 | ALKYLAMINO SUBSTITUTED TRIAZINEDIONES, TRIAZINEMONOTHIONES AND TRIAZINEDITHIONES | TOCRIS COOKSON LIMITED (GB) | 1994-10-13 | — | — | WO | disclosed |
| EP-0604183-A1 | Inhibitors of HIV protease useful for the treatment of aids | ELI LILLY AND COMPANY (US) | 1994-06-29 | — | — | EP | disclosed |
| US-5063208-A | Cardiovascular disorders, vision defects | ABBOTT LABORATORIES (US) | 1991-11-05 | — | — | US | disclosed |
| EP-0410260-A2 | Peptidyl aminodiol renin inhibitors | ABBOTT LABORATORIES (US) | 1991-01-30 | — | — | EP | disclosed |
| WO-1989010751-A1 | FUNCTIONALIZED PEPTIDYL AMINODIOLS AND -TRIOLS | ABBOTT LABORATORIES (US) | 1989-11-16 | — | — | WO | disclosed |
| EP-0307837-A2 | Renin-inhibiting peptidyl heterocycles | ABBOTT LABORATORIES (US) | 1989-03-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260070930-A1 | RAS INHIBITORS | KRAS, NRAS, RIN1 | GAA 2997/4885NFKB1 2370/4885NFKB2 2274/4885 |
| US-20250376464-A1 | Compounds for treatment a coronavirus infection | ACE2, ACE, TMPRSS2 | GAA 600/4885NFKB1 3277/4885NFKB2 3362/4885 |
| US-20250319187-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | GAA 2164/4885NFKB1 1867/4885NFKB2 1962/4885 |
| US-12624053-B2 | Ras inhibitors | KRAS, NRAS, HMGCR | GAA 2020/4885NFKB1 2180/4885NFKB2 2269/4885 |
| US-20250255964-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | GAA 2164/4885NFKB1 1867/4885NFKB2 1962/4885 |
| US-12403196-B2 | Ras inhibitors | KRAS, NRAS, HRAS | GAA 2164/4885NFKB1 1867/4885NFKB2 1962/4885 |
| US-12465643-B2 | Ras inhibitors | KRAS, NRAS, HRAS | GAA 2164/4885NFKB1 1867/4885NFKB2 1962/4885 |
| US-20250242029-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | GAA 2164/4885NFKB1 1867/4885NFKB2 1962/4885 |
| US-20250388608-A1 | RAS INHIBITORS | KRAS, NRAS, HMGCR | GAA 2020/4885NFKB1 2180/4885NFKB2 2269/4885 |
| US-12409225-B2 | Ras inhibitors | KRAS, NRAS, HRAS | GAA 2164/4885NFKB1 1867/4885NFKB2 1962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.